|
Model behavior
December 2015
EDIT CONNECT
SHARING OPTIONS:
SANTA CLARA, Calif.—Crown Bioscience has announced an exclusive preclinical services alliance applying its collection of
naturally occurring diabetic translational models. While no details were disclosed, Crown’s models are known to cover a variety of indications. The
translational models are designed for research into a variety of cardiovascular and metabolic diseases, including spontaneous developed diabetes and its
complications, such as diabetic nephropathy, left ventricular diastolic dysfunction, fatty liver and diet-induced dyslipidemia, among others. They are
designed to mimic aspects of human disease related to obesity, nephropathy, hyperglycemia, hyperinsulinemia, dyslipidemia, glucose intolerance, reduced
glucose disposition, insulin resistance and late-stage insulin dependency.
“Our translational models give
sponsors a high level of confidence when deciding to move a drug candidate into clinical development by providing insights into the pharmacological
mechanisms of a drug and identifying biomarkers important to clinical trial design,” Dr. Jean-Pierre Wery, president of Crown, said in a press
release.
The company also announced in early November that it houses the world’s largest commercially
available portfolio of small cell lung cancer patient-derived xenograft (PDX) models. Crown has developed the HuPrime and PDXact Jumpstart collections of
small cell lung cancer models, and a majority of the 70 models have RNA sequence data, with more than half also featuring in-vivo standard-of-care
data.
It’s far from the only news for Crown in the translational sphere lately. The company also hosted a
symposium in September for some of the industry’s leading experts to discuss recent scientific discoveries in translational oncology. Among the covered
topics, Dr. Henry Li, vice president of translational oncology at Crown, discussed the molecular pathway of PDX diseases, while Dr. Tommy Broudy, general
manager and chief scientific officer at Crown Bioscience San Diego, lectured on the adoption of clinically relevant models in oncology therapeutics. Dr.
Christopher Murriel, chair of the symposium and a senior scientist in the department of cancer biology at OncoMed Pharmaceuticals, held forth on the use of
patient-derived and murine tumor models to predict impacts on cancer stem cells and antitumor immunity.
“Some of the foremost researchers in this field shared information about immuno-oncology therapies and their impact on translational
oncology,” Murriel remarked of the event. “Translational research, particularly in oncology, holds tremendous potential toward therapeutic drug
development and clinical advancement—and the scientists at this symposium presented exciting research that demonstrates how much opportunity
exists.”
On Nov. 4, Crown hosted another symposium, this one at the Boston Museum of Science and held a day
before the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The symposium, titled “Translational Oncology and the
Rise of Immunotherapy...a Global Challenge That Requires a Personal Touch,” focused on recent developments in translational research, including
improving clinical relevance, predictive biomarker development and genomic approaches to personalized medicine. Li and Murriel spoke at the event, as did Dr.
Qian Shi, Crown’s vice president of cancer pharmacology, and they were also joined by speakers from Takeda Pharmaceuticals International Co.,
MedImmune, Merck & Co. and Tesaro Inc.
“The objective of the symposium is to foster a greater
understanding of translational technologies in both research and clinical communities,” Wery remarked. “These technologies connect the
preclinical and clinical aspects of drug development and provide decision support tools as companies advance therapeutic candidates. Our goal is to share the
latest scientific discoveries to help researchers identify the best candidates for clinical development.”
Crown also recently announced that Dr. Zhen Pang, a recognized expert in transgenic models, had joined the company as its scientific director. Pang
has previously held key positions as principal research investigator at a number of global biopharmaceutical companies, with experience in multiple
therapeutic areas, including metabolic diseases.
“We are experiencing substantial growth in demand for our
cardiovascular and metabolic disease (CVMD) services because of our depth and capability in cardiovascular and diabetic research,” remarked Dr. Jim
Wang, senior vice president of CVMD research at Crown Bioscience. “With the expansion of our CVMD program in the U.S. and China, as well as the
appointment of Dr. Pang, we are able to provide cutting-edge translational platforms and cost-effective drug development solutions to top pharmaceutical
companies worldwide.”
Code: E121505 Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|